SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results – Yahoo Finance
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 2022. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company’s website at www.siga.com under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-844-826-3033 for domestic callers or 1-412-317-5185 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 10171319. The archived webcast will be available in the Events and Presentations section of the Company’s website.
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.
About Smallpox
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally-occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine’s side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the progress of SIGA’s development programs and timelines for bringing products to market, delivering products to the Strategic Stockpile, the enforceability of our procurement contracts, such as the 19C BARDA Contract (the “BARDA Contract”), with BARDA, the impact of the COVID pandemic and responding to the global outbreak of monkeypox. The words or phrases “can be,” “expects,” “may affect,” “may depend,” “believes,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the BARDA Contract, not to exercise all, or any, of the remaining unexercised options under those contracts, (ii) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contract, the current Department of Defense procurement contract or PEP Label Expansion R&D Contract (as defined in the Form 10-Q) are modified or canceled at the request or requirement of the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX® internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiii) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xiv) the risk that the U.S. or foreign governments’ responses (including inaction) to national or global economic conditions or infectious diseases, such as COVID-19, are ineffective and may adversely affect SIGA’s business, and (xv) risks associated with responding to the current monkeypox outbreak, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 and SIGA’s subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC’s website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
Contacts:
Investor Contact
Laine Yonker, Edison Group
lyonker@edisongroup.com
Michael Crawford, Edison Group
mcrawford@edisongroup.com
Public Relations
Holly Stevens, Berry & Company
hstevens@berrypr.com
Related Quotes
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the second quarter fiscal year 2023 ended September 30, 2022 before financial markets open on November 9, 2022.
The biotech company cited changes in regulatory timelines and requirements and 'diminishing government financial support' among the key reasons for its decision.
Gilead Sciences reported 79% growth for its cancer drugs, helping beat expectations. On Friday, GILD stock broke out.
Recent IPO stock Nuvalent Therapeutics surged within striking distance of a record high Friday on promising test results in lung cancer.
Bristol Myers Squibb's management team was quick to point to the strong performance of several new drugs in its portfolio. Bristol Myers Squibb CEO Giovanni Caforio noted in the Q3 results press release that the company has launched nine new products over the last three years, with three of them coming in 2022. Bristol Myers Squibb's share price is up around 17%, trouncing the performance of the S&P 500.
Having no symptoms after getting the shot doesn’t mean it didn’t work.
Truist's Robyn Karnauskas and Piper Sandler's Do Kim lifted their ratings to Buy and Overweight, respectively, from the equivalent of Hold.
The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 13 to 3 votes in favor of GSK plc's (NYSE: GSK) daprodustat for adult dialysis patients with anemia of chronic kidney disease (CKD). In adult non-dialysis patients with anemia of CKD, the CRDAC did not support that the benefit of treatment with daprodustat outweighs the risks with a 5 to 11 vote. In April 2022, the FDA accepted the daprodustat marketing application and assigned a Prescription Drug User Fee Act date of 1 Fe
Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.
(Reuters) -French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price. Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%. It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.
There are pros and cons to investing in biotech stocks. One of the advantages is that shares of drugmakers can explode in a short period, especially following regulatory or clinical wins. On the other hand, the industry tends to be volatile, which may not suit some people's investment styles.
Recent small studies, not yet peer-reviewed, suggested the new boosters may not be significantly better than the original vaccine formula.
(Reuters) -GSK Plc came closer to securing its first drug approval since its consumer health spin-off in July as an expert panel of the U.S. health regulator backed an approval for its drug to treat anemia in some patients with chronic kidney disease (CKD). The advisers to the Food and Drug Administration on Wednesday voted 13-3 in favor of the oral drug for patients on dialysis, although GSK was expecting approval for a broader CKD population. "The statistical data (was)… more reassuring for this population than for the ND (not on dialysis) population," said panelist Thomas Wang from UT Southwestern Medical Center in Texas.
A viral claim that a Pfizer executive supposedly "admitted to the European Parliament" in October 2022 that the company's Covid-19 vaccine has not been tested on preventing coronavirus transmission omits important details about clinical trials for the jab. This information is not new as the misleading posts allege; it has been publicly reported by the company, health agencies, and multiple news media since December 2020. Pfizer's clinical trials were designed to measure its vaccine's effectivene
(Bloomberg) — Credit Suisse Group AG opted to tap investors for a painful multibillion-dollar capital raise to shore up confidence and fund a years-long reshaping that will carve out its investment bank and slash its headcount by 9,000. Most Read from BloombergNew Covid Boosters Aren’t Better Than Old Ones, Study FindsMusk Tells Twitter Staff He Doesn’t Plan to Cut 75% Of JobsUS Warns South African Economic Hub May Be Terror TargetMark Zuckerberg’s Wealth Wipeout Hits $100 Billion as Meta Misse
(Bloomberg) — The brutal selloff across asset classes this year now makes the famed 60/40 stock-bond portfolio ripe for its best outlook in years, according to UBS analysts.Most Read from BloombergTesla Engineers Visit Twitter Office to Review Code for MuskMusk Takes Twitter Helm, Enacts Sweeping Change as Deal ClosesTwitter CEO Among Top Executives Departing as Musk Takes OverMark Zuckerberg’s Wealth Wipeout Hits $100 Billion as Meta Misses AgainFed Seen Aggressively Hiking to 5%, Triggering G
Meta Platforms Inc. on Wednesday became the latest tech titan tattooed by a precipitous drop in digital advertising, reporting less than half the profit it had in the same quarter a year ago and sending its stock plummeting toward the lowest prices in more than six years.
The European Central Bank announced a second 75-basis-point interest-rate increase in as many months on Thursday, meeting economists’ expectations with inflation riding at a record-high 9.9%. The euro weakened against the dollar, even as Treasury yields softened, as investor concern about future growth seems to be intensifying. Meanwhile, the U.S. economy expanded at an annualized pace of 2.6% during the third quarter. Global Markets Editor Weston Nakamura joins Maggie Lake live in Real Vision’s New York studio for a special edition of the Daily Briefing to talk about the new “widow-maker” trade and the dilemma central bankers face, illustrated by the Bank of Japan’s money-printing into the Ministry of Finance’s yen-buying. Weston discusses in greater depth the emerging conflicts between governments and their central banks here: https://rvtv.io/3DhzACD. And we want to hear from you too – please share your questions, comments, and suggestions! Editor’s Note: Our live chat feature will be unavailable for four to six weeks as we upgrade our video player technology. We apologize for the temporary loss of function. But we assure you the upgrade will more than justify the wait. In the meantime, we will be monitoring the comments section. So, in addition to conversing with your fellow community members, please share your questions there.
Applied Materials (AMAT) closed at $88.14 in the latest trading session, marking a +0.7% move from the prior day.
Does Cummins (CMI) have what it takes to be a top stock pick for momentum investors? Let's find out.